Compare Vital Farms Inc (VITL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vital Farms Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Vital Farms Inc trades at $9.44 (market cap $405.27M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 314.7× Vital Farms Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vital Farms Inc for 14 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| VITL | VRTX | |
|---|---|---|
Market Cap | $405.27M | $127.55B |
Volume | 1,810,837 | 1,487,944 |
Sector | Consumer Staples | Health |
52-Week High | $43.68 | $557.96 |
52-Week Low | $8.28 | $407.37 |
Typical Hold Time | 14 Days | 120 Days |
Enterprise Value | $492.28M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vital Farms (VITL) trades at $9.24, down 1.7% on the day, reflecting ongoing pressure from weak earnings and industry headwinds. The stock shows a bearish technical trend with key support at $9.00, while fundamentals reveal a sharp decline in profitability with a net margin of just 0.02% in 2026. Recent news highlights strategic review discussions and institutional acquisitions, yet negative cash flow and pricing challenges in the egg market weigh on investor confidence.
The outlook remains cautious with significant execution risks amid industry oversupply, though analyst consensus suggests upside potential to a $13.11 price target. Investment opportunity hinges on a successful strategic review and margin recovery, but risks include sustained cash burn and competitive pressures that could limit near-term gains.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
